Press Release Lilly’s olomorasib receives U.S. FDA’s Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer Aug 3
Press Release Lilly confirms date and conference call for second-quarter 2026 financial results announcement Jul 22